In a recent poll of gene synthesis customers, more than 70 per cent of respondents rated the protection of intellectual property as important or very important, with a striking 56 per cent rating it as “very important” to their choice of a gene synthesis vendor.
Intellectual property is the cornerstone of the life science industry. Specific sequences of DNA that are utilized in drug discovery, research on biofuels, or the development of more resilient crops or that help us better understand the underpinnings of life are certainly some of the most fundamental elements of intellectual property in existence.
“DNA2.0 understands the great value of the intellectual property contained in many gene synthesis orders,” said Claes Gustafsson, Co-Founder and Vice President at DNA2.0. “This is why every single gene sold by DNA2.0 is made at the company’s state-of-the-art facility in Menlo Park, Calif., thus ensuring the greatest security for patented and confidential sequences. DNA2.0 guarantees researchers high-quality synthetic genes that are always delivered on time.”
Most major gene suppliers manufacture their genes in countries with lax IP protection and in some cases do so without their customers’ knowledge. Start-ups are particularly vulnerable as they often do not possess the legal resources to protect their intellectual property.
“In addition to making all of our genes in the USA, we pride ourselves on providing relentless customer service and PhD-level support,” said Louise Rafty, Director of Sales at DNA2.0 “Our success in providing excellent service and support is reflected in our customers’ response to this survey.”
DNA2.0 customers reported great satisfaction with their experience, noting that DNA2.0’s genes “have always been the highest quality” and that they have “been very happy with DNA2.0’s overall quality, pricing and turnaround time.” In the words of one DNA customer, “I wouldn’t use any other company for gene design.”
The survey was based on 263 responses, tallied between January 2009 and June 2010.
About DNA2.0, Inc.
Founded in 2003, DNA2.0 is the leading synthetic biology company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif.
For more information, please visit www.DNA20.com or email Claes Gustafsson, VP Sales cgustafsson@DNA20.com.